Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

408
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

554
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
554

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating Patient Medians for Laboratory Quality Control Using Long-Term Carbamazepine Monitoring Data.

The journal of applied laboratory medicine·2026
Same author

Genomic Medicine Sweden: Advancing precision medicine at the national level.

Journal of internal medicine·2026
Same author

Risk of venous thromboembolism after SARS-CoV-2 vaccination-Evidence from genome-wide association study and population-based observational study.

British journal of clinical pharmacology·2026
Same author

HLA-B*44 Alleles and HLA-DQA1*03:01 as Genetic Risk Factors for Drug-Induced Liver Injury due to Fluoroquinolones.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

The 8th European Society of Pharmacogenomics and Personalized Therapy (ESPT) congress.

Pharmacogenomics·2026
Same author

Bedside treatment algorithm for safe administration of 24-hour high-dose methotrexate in adult acute lymphoblastic leukemia.

Haematologica·2026

Related Experiment Video

Updated: May 3, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K

Pharmacogenetics-based warfarin dosing in children.

Anna-Karin Hamberg1, Mia Wadelius

  • 1Department of Medical Sciences, Division of Clinical Pharmacology, Uppsala University, SE-751 85 Uppsala, Sweden.

Pharmacogenomics
|February 19, 2014
PubMed
Summary

Pharmacogenetic models for warfarin dosing in children are reviewed. Studies show clinical factors, CYP2C9, and VKORC1 gene variations influence pediatric warfarin dose variability, but model performance varies.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K
Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

1.5K

Related Experiment Videos

Last Updated: May 3, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K
Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

1.5K

Area of Science:

  • Pharmacogenomics
  • Pediatric pharmacology
  • Drug dose optimization

Background:

  • Warfarin dose variability is influenced by clinical factors and genetic variations (CYP2C9, VKORC1) in adults.
  • Limited and conflicting data exist on the importance of these factors for pediatric warfarin dose requirements.
  • Existing pharmacogenetic models for pediatric warfarin dosing require critical evaluation.

Purpose of the Study:

  • To critically review published pharmacogenetic-based prediction models for warfarin dosing in children.
  • To compare the predictive performance of these models in a distinct cohort of pediatric patients.
  • To identify knowledge gaps and necessary properties for improved pediatric warfarin therapy models.

Main Methods:

  • Systematic literature review of pharmacogenetic warfarin dosing models in pediatric populations.
  • Head-to-head comparison of predictive model performance using a distinct cohort of warfarin-treated children.
  • Analysis of clinical factors, demographic variables, and gene variations (CYP2C9, VKORC1) in relation to dose requirements.

Main Results:

  • Published pharmacogenetic models show variable predictive performance for pediatric warfarin dosing.
  • Clinical factors and genetic variations (CYP2C9, VKORC1) contribute to dose variability, but their relative importance in children is not fully elucidated.
  • Performance comparison highlights inconsistencies and limitations of current prediction models in diverse pediatric cohorts.

Conclusions:

  • Current pharmacogenetic models for pediatric warfarin dosing require refinement and validation.
  • Further research is needed to address knowledge gaps and develop robust models for optimizing warfarin therapy in children.
  • Improved models are essential for safe and effective warfarin use across all pediatric age groups.